We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
- Authors
Lucas, David M; Alinari, Lapo; West, Derek A; Davis, Melanie E; Edwards, Ryan B; Johnson, Amy J; Blum, Kristie A; Hofmeister, Craig C; Freitas, Michael A; Parthun, Mark R; Wang, Dasheng; Lehman, Amy; Zhang, Xiaoli; Jarjoura, David; Kulp, Samuel K; Croce, Carlo M; Grever, Michael R; Chen, Ching-Shih; Baiocchi, Robert A; Byrd, John C
- Abstract
While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies.
- Publication
PloS one, 2010, Vol 5, Issue 6, pe10941
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0010941